Andrew Schally

Dr. Andrew V. Schally, a Nobel Laureate in Medicine, is continuing his work on the development and preclinical evaluation of peptide analogs with antitumor activity. This program is aimed at providing a theoretical, preclinical, and mechanistic basis for planned clinical trials with these peptide analogs in various cancers, including prostatic, pancreatic, gastric, colorectal, malignant brain tumors, small cell lung cancer and non-small cell lung cancer, bladder cancer, renal and thyroid cancer, osteosarcomas, melanomas, hepatocellular carcinoma, and lymphomas. Overall, this program has the potential to make a significant impact on the improvements of therapeutic methods and the delivery of care to the patients afflicted with various cancers. Updated July 2017